Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.
- NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_assertion description "[Despite increasing use of targeted therapy, interleukin-2 (IL-2) is unique, because this cytokine can induce long-term remissions in 5% to 7% of patients with metastatic melanoma and renal cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.
- NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_assertion evidence source_evidence_literature NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.
- NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_assertion SIO_000772 21577143 NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.
- NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_assertion wasDerivedFrom befree-2016 NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.
- NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_assertion wasGeneratedBy ECO_0000203 NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.
- befree-2016 importedOn "2016-02-19" NP894727.RAl263qXmGa9JUJ9F-zC0HQG-9QvkOBOS1mkWgFEvvndU130_provenance.